Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum D, Gaudray P, Theillet C
First Department of Obstetrics and Gynecology, Allgemeines Krankenhaus, Vienna, Austria.
Genes Chromosomes Cancer. 1994 Jan;9(1):42-8. doi: 10.1002/gcc.2870090108.
In an attempt to verify the nature of amplification events at band q13 on chromosome 11 we surveyed the amplification status of ten molecular markers specific for this region (GSTP, SEA, D11S97, D11S146, BCLI, PRADI/CCNDI, HST/FGF4, INT2/FGF3, EMSI, and DIIS833E) in a panel of 389 primary breast carcinoma DNA samples. Eighty-eight tumors (23%) showed at least one of these markers amplified, but in a majority of the cases amplification encompassed more than one of the tested loci. Our data confirm that amplicons at 11q13 can cover large portions of DNA and are consistent with the existence of several cores of amplification. One important core seems to be, as previously described, centered around PRADI/CCNDI; 57 tumors (14.7%) showed amplification at PRADI/CCNDI either alone (one tumor) or along with amplification of BCLI or INT2/FGF3. The level of amplification of PRADI/CCNDI sometimes exceeded that of surrounding markers. Three additional amplification events occurring independently of amplification of PRADI/CCNDI were also detected. Centromeric to BCLI, probes to DIIS97, and DIIS146 detected amplification in 60 tumors (15.4%) and were often the only amplified markers. Telomeric to INT2/FGF3, DIIS833E was found amplified alone in ten tumors, and it was the most amplified marker in another six cases. At a shorter distance of INT2/FGF3, EMSI was the only amplified marker in two tumors, with a level of amplification that could exceed that of PRADI/CCNDI and DIIS833E. Our data thus suggest the existence of four independent amplified regions within band 11q13 in breast cancer.
为了验证11号染色体q13带扩增事件的性质,我们检测了389份原发性乳腺癌DNA样本中针对该区域的10个分子标记(GSTP、SEA、D11S97、D11S146、BCLI、PRADI/CCNDI、HST/FGF4、INT2/FGF3、EMSI和DIIS833E)的扩增状态。88个肿瘤(23%)显示这些标记中至少有一个扩增,但在大多数情况下,扩增涉及多个检测位点。我们的数据证实,11q13处的扩增子可覆盖大片段DNA,与存在多个扩增核心一致。如先前所述,一个重要的核心似乎以PRADI/CCNDI为中心;57个肿瘤(14.7%)显示PRADI/CCNDI单独扩增(1个肿瘤)或与BCLI或INT2/FGF3一起扩增。PRADI/CCNDI的扩增水平有时超过周围标记。还检测到另外三个独立于PRADI/CCNDI扩增发生的扩增事件。在BCLI着丝粒侧,针对DIIS97和DIIS146的探针在60个肿瘤(15.4%)中检测到扩增,且它们常常是唯一扩增的标记。在INT2/FGF3端粒侧,DIIS833E在10个肿瘤中单独扩增,在另外6个病例中它是扩增程度最高的标记。在距离INT2/FGF3较近的位置,EMSI是两个肿瘤中唯一扩增的标记,其扩增水平可能超过PRADI/CCNDI和DIIS833E。因此,我们的数据表明乳腺癌11q13带内存在四个独立的扩增区域。